eTable 1. Secondary outcome adverse event rates, by age group and pregnancy status

Adverse Event[a]	6 months–4 years	5–14 years	15–39 years	40–64 years	≥65 years	Pregnant[b]	Total
Pain at the injection site	113/5,979 (1.9)	86/4,266 (2.0)	255/13,020 (2.0)	419/20,953 (2.0)	354/27,222 (1.3)	36/1,963 (1.8)	1,227/71,440 (1.7)
Tired/fatigued[c]	83/5,571 (1.5)	52/4,249 (1.2)	183/12,862 (1.4)	368/20,661 (1.8)	331/27,069 (1.2)	22/1,961 (1.1)	1,017/70,412 (1.4)
Swelling and/or redness at the injection site[d]	95/5,968 (1.6)	71/4,255 (1.7)	172/12,875 (1.3)	306/20,692 (1.5)	289/27,127 (1.1)	24/1,963 (1.2)	933/70,917 (1.3)
Headache[c]	7/5,567 (0.1)	42/4,247 (1.0)	155/12,859 (1.2)	286/20,659 (1.4)	231/27,060 (0.9)	26/1,960 (1.3)	721/70,392 (1.0)
Sleep pattern change[c]	55/5,570 (1.0)	28/4,248 (0.7)	53/12,851 (0.4)	111/20,648 (0.5)	101/27,029 (0.4)	5/1,960 (0.3)	348/70,346 (0.5)
Irritable[c]	94/5,571 (1.7)	21/4,245 (0.5)	56/12,855 (0.4)	77/20,641 (0.4)	56/27,016 (0.2)	5/1,961 (0.3)	304/70,328 (0.4)
Rash[e]	31/5,979 (0.5)	10/4,266 (0.2)	26/13,020 (0.2)	40/20,953 (0.2)	70/27,222 (0.3)	1/1,963 (0.1)	177/71,440 (0.2)
Vomiting[c]	29/5,568 (0.5)	8/4,246 (0.2)	33/12,849 (0.3)	27/20,643 (0.1)	12/27,011 (0.04)	9/1,960 (0.5)	109/70,317 (0.2)
Diarrhea[c]	15/5,567 (0.3)	4/4,246 (0.1)	26/12,851 (0.2)	41/20,644 (0.2)	33/27,018 (0.1)	3/1,960 (0.2)	119/70,326 (0.2)
Rigors[f]	7/5,579 (0.1)	3/4,257 (0.1)	15/12,997 (0.1)	34/20,903 (0.2)	34/27,113 (0.1)	2/1,960 (0.1)	93/70,849 (0.1)
Non-responsiveness/loss of consciousness[c]	0/5,567 (0.0)	0/4,245 (0.0)	0/12,848 (0.0)	1/20,637 (0.005)	2/27,010 (0.007)	0/1,960 (0.0)	3/70,307 (0.004)
Convulsions/seizures[g]	0/5,979 (0.0)	0/4,266 (0.0)	0/13,020 (0.0)	0/20,953 (0.0)	2/27,222 (0.007)	0/1,963 (0)	2/71,440 (0.003)
Other[h]	86/5,979 (1.4)	28/4,266 (0.7)	88/13,020 (0.7)	196/20,953 (0.9)	247/27,222 (0.9)	13/1,963 (0.7)	645/71,440 (0.9)

[a] Denominators differ between adverse events because symptoms are solicited in an online survey following the initial SMS regarding an AEFI, and not all participants complete the survey.
[b] Pregnant participants are also included in their respective age categories (age range: 15–49 years).
[c] Collected by SmartVax only.
[d] SmartVax and STARSS collect data on injection site swelling and/or redness in one question, while Vaxtracker has separate questions for injection site redness and injection site swelling. The Vaxtracker data for injection site redness and injection site swelling have been combined for this table.
[e] STARSS specifies that the rash is over a large area of the body.
[f] SmartVax includes a description ("shaking or shivering with high temperature"), while STARSS and Vaxtracker do not refer to rigors and instead collect data on "chills and shakes".
[g] SmartVax collects data on "convulsions/seizures", while Vaxtracker collects information on "seizures", and STARSS collects information on "seizures or fits".
[h] A free-text response box is provided for participants responding that they had an "Other" reaction to describe the event(s).